BioWa And Aphton Corporation Announce Licensing Of BioWa's POTELLIGENT(TM) Technology

PRINCETON, N.J. & PHILADELPHIA, Pa.--(BUSINESS WIRE)--Feb. 14, 2006--BioWa, Inc. and Aphton Corporation (Pink Sheets:APHT) today announced that BioWa has granted a non-exclusive license to Apthon's wholly-owned subsidiary, Igeneon, to use BioWa's POTELLIGENT(TM) technology for the development of IGN312, a humanized monoclonal Lewis Y-specific antibody. Aphton, through Igeneon, develops IGN312 as a next-generation antibody based on IGN311, which is currently in a Phase I/II clinical trial in patients with Lewis Y-positive cancers.